非布司他片和别嘌醇片治疗高尿酸血症的成本-效果分析  

Cost-Effectiveness Analysis of febuxostat and allopurinol in hyperuricemia Fibrosis

作　　者：陈月[1] 郭静[1] 王鹏[1] 张海英[1] CHEN Yue;GUO Jing;WANG Peng;ZHANG Hai-ying(Department of Pharmacy,People's Hospital,Peking University,Beijing 100044,China)

机构地区：[1]北京大学人民医院,100044

出　　处：《首都食品与医药》2021年第11期47-49,共3页Capital Food Medicine

摘　　要：目的评价非布司他片与别嘌醇片治疗高尿酸血症的成本-效果.方法构建决策树模型,收集成本和效果参数,考察24周内非布司他和别嘌醇治疗高尿酸血症的成本-效果,并进行确定性敏感性分析及概率敏感性分析,评估参数变化对研究的影响.结果与别嘌醇组相比,非布司他组24周治疗费用合计多花2793.23元,增量成本效果(ICER=456.85元)低于支付意愿值(WTP=212676元),回乘分析的结果也显示了非布司他组为优势方案.确定性因素敏感性分析中,飓风图显示对结果影响最显著的变量为E1;概率敏感性分析结果显示对3倍人均GDP的成本效果阈值下,非布司他组有成本效果优势.结论非布司他治疗高尿酸血症,血尿酸达标率更高,提高了患者的生存质量.在3倍人均GDP的阈值下,非布司他治疗高尿酸血症是一种经济有效的治疗方法.Objective To evaluate the costeffectiveness of febuxostat and allopurinol tablets in the treatment of hyperuricemia.Methods A decision tree model was constructed to investigate the cost-effectiveness of febuxostat and allopurinol in hyperuricemia treatment within 24 weeks.DSA and PSA were conducted to evaluate the influence of parameter changes on the study.Results compared with allopurinol group,febuxostat group spent 2793.23 yuan more for 24 weeks of treatment.ICER was lower than WTP.And the results of roll back also indicated that febuxostat group was the preferred regimen.DSA shows the impact on the results of the most significant variable for E1.The results of PSA showed that febuxostat group had a cost-effectiveness advantage under the costeffectiveness threshold of 3 times per capita GDP.Conclusion Febuxostat in the treatment of hyperuricemia can improve the quality of life of patients with hyperuricemia.Febuxostat is a cost-effective treatment for hyperuricemia at a threshold of 3 times GDP per capita.

关 键 词：非布司他片 别嘌醇片 高尿酸血症 成本-效果 

分 类 号：R971.1[医药卫生—药品]